Holen Sie sich die Stockscreener-App
7.47
1.63%
0.12
Handel nachbörslich:
7.52
0.05
+0.67%
Schlusskurs vom Vortag:
$7.35
Offen:
$7.38
24-Stunden-Volumen:
30,561
Relative Volume:
0.29
Marktkapitalisierung:
$37.28M
Einnahmen:
$34.77M
Nettoeinkommen (Verlust:
$-74.04M
KGV:
-0.9456
EPS:
-7.9
Netto-Cashflow:
$-79.76M
1W Leistung:
+4.92%
1M Leistung:
+25.13%
6M Leistung:
-38.11%
1J Leistung:
-83.12%
1-Tages-Spanne:
$7.26
$7.5311
1-Wochen-Bereich:
$6.6319
$7.70
52-Wochen-Spanne:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
7.47 | 36.68M | 34.77M | -74.04M | -79.76M | -7.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.37 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
468.58 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.20 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
763.52 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
335.67 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Eingeleitet | William Blair | Outperform |
| 2024-11-15 | Fortgesetzt | Citigroup | Buy |
| 2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Herabstufung | Truist | Buy → Hold |
| 2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Eingeleitet | Guggenheim | Buy |
| 2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Eingeleitet | Citigroup | Buy |
| 2022-11-21 | Eingeleitet | Truist | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-04-29 | Eingeleitet | BTIG Research | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
Price Action Confirms Reversal in Mersana Therapeutics Inc. TrendJuly 2025 Patterns & Weekly Top Performers Watchlists - beatles.ru
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High? - Yahoo Finance
Mersana Therapeutics Inc. Recovers — But Is It SustainableJuly 2025 Price Swings & Low Risk High Win Rate Stock Picks - beatles.ru
Can Mersana Therapeutics Inc. reach resistance levels soonQuarterly Trade Review & AI Powered Market Trend Analysis - beatles.ru
Mersana Therapeutics Faces Nasdaq Non-Compliance Notice - MSN
Can Mersana Therapeutics Inc. stock double in the next year2025 Institutional Moves & Daily Market Momentum Tracking - خودرو بانک
Is Mersana Therapeutics Inc. stock forming a cup and handleJuly 2025 Analyst Calls & Stock Portfolio Risk Management - خودرو بانک
Published on: 2025-09-05 14:49:22 - Newser
What does recent volatility data suggest for Mersana Therapeutics Inc.Trade Entry Summary & Fast Gain Stock Trading Tips - Newser
How sentiment analysis helps forecast Mersana Therapeutics Inc.2025 Trading Recap & Risk Controlled Stock Alerts - Newser
Can Mersana Therapeutics Inc. deliver alphaJuly 2025 Sector Moves & Technical Buy Zone Confirmation - خودرو بانک
Key resistance and support levels for Mersana Therapeutics Inc.Quarterly Performance Summary & Daily Market Momentum Tracking - Newser
Using Bollinger Bands to evaluate Mersana Therapeutics Inc.Weekly Trade Summary & Real-Time Buy Signal Notifications - Newser
Published on: 2025-09-05 05:23:37 - Newser
What Fibonacci levels say about Mersana Therapeutics Inc. reboundJuly 2025 Breakouts & Weekly Setup with High ROI Potential - Newser
What data driven models say about Mersana Therapeutics Inc.’s futureAnalyst Downgrade & Safe Swing Trade Setup Alerts - Newser
Mersana Therapeutics Inc. recovery potential after sell offQuarterly Profit Report & Long-Term Investment Growth Plans - Newser
Mersana Therapeutics’ Earnings Call Highlights Progress and Challenges - MSN
How sensitive is Mersana Therapeutics Inc. to inflation2025 Winners & Losers & AI Powered Trade Plan Recommendations - خودرو بانک
Is Mersana Therapeutics Inc. reversing from oversold territoryMarket Performance Report & Real-Time Market Sentiment Alerts - Newser
How volatile is Mersana Therapeutics Inc. stockWeekly Trade Report & Long Hold Capital Preservation Tips - خودرو بانک
Will Mersana Therapeutics Inc. face regulatory challengesJuly 2025 Drop Watch & Reliable Breakout Stock Forecasts - khodrobank.com
Is Mersana Therapeutics Inc. stock reversal real or fake2025 EndofYear Setup & Risk Managed Investment Signals - Newser
Will Mersana Therapeutics Inc. outperform the marketStop Loss & High Accuracy Swing Entry Alerts - Newser
Is Mersana Therapeutics Inc. a top pick in the sectorDividend Hike & Weekly Market Pulse Updates - خودرو بانک
Has Mersana Therapeutics Inc. formed a bullish divergenceMarket Risk Summary & Proven Capital Preservation Methods - Newser
Best data tools to analyze Mersana Therapeutics Inc. stockMarket Volume Summary & Low Risk Entry Point Guides - Newser
Evaluating Mersana Therapeutics Inc. with trendline analysisRisk Management & Risk Managed Trade Strategies - Newser
Leading vs lagging indicators on Mersana Therapeutics Inc. performanceJuly 2025 Analyst Calls & Weekly High Momentum Picks - Newser
Analyzing net buyer seller activity in Mersana Therapeutics Inc.July 2025 Technicals & Verified Momentum Stock Alerts - Newser
What recovery options are there for Mersana Therapeutics Inc.2025 Technical Overview & Verified Trade Idea Suggestions - Newser
Will Mersana Therapeutics Inc. bounce back from current support2025 Technical Overview & Accurate Intraday Trade Tips - Newser
How moving averages guide Mersana Therapeutics Inc. tradingWeekly Stock Report & Risk Controlled Swing Alerts - Newser
Using Python tools to backtest Mersana Therapeutics Inc. strategiesAnalyst Upgrade & Weekly Return Optimization Plans - Newser
Using data tools to time your Mersana Therapeutics Inc. exitEarnings Growth Report & Entry Point Confirmation Alerts - Newser
Can Mersana Therapeutics Inc. generate free cash flowJuly 2025 Summary & Consistent Return Strategy Ideas - خودرو بانک
Sector ETF performance correlation with Mersana Therapeutics Inc.Options Play & High Win Rate Trade Tips - Newser
Can momentum traders help lift Mersana Therapeutics Inc.2025 Market Sentiment & Stepwise Entry/Exit Trade Alerts - Newser
Ranking Mersana Therapeutics Inc. among high performing stocks via toolsWeekly Trend Report & Weekly Setup with ROI Potential - Newser
Chart based exit strategy for Mersana Therapeutics Inc.2025 Market Outlook & Real-Time Buy Zone Alerts - Newser
Is now a turning point for Mersana Therapeutics Inc.Trade Exit Summary & High Return Trade Opportunity Guides - Newser
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):